It’s complicated. I started using Afrezza when it first became available in the US in March 2015. I first used it for meals and corrections but transitioned to primarily using it for corrections. On average, I use 4 doses/day of 4-units. It works wonderfully for me.
I can correct in the middle of the night without fear of overdoing it. I will correct BGs as low as 120 in the right conditions. Afrezza is another tool in my diabetes toolbox.
Mannkind, Afrezza’s producer, emerged as a renegade in this field and market. Al Mann, the company’s founder was an engineer, not a medical doctor or researcher. He designed and built MiniMed insulin pumps back in ‘80s before selling the company to Medtronic in the early 2000s.
The FDA delayed introduction of the product three times but Al Mann persisted, often solely funding the enterprise. I believe that the medical/research/academic members of the status quo took an undue degree of skepticism toward Afrezza.
As a result, to this day, most doctors are unfamiliar with it. The FDA certified its use only with a “black box” warning about potential breathing problems and a required periodic respiratory test. Four years in the market with little, if any, respiratory incidence has still not quelled clinician’s uncertainty about this product.
I think it’s a wonderful product that I wouldn’t want to live without. Sometimes when I forget to prebolus for a meal, I use Afrezza instead and it works very well.
I hope your experience is just a good as mine has been.